FC
SUPN icon

Financial Consulate’s Supernus Pharmaceuticals SUPN Stock Holding History

Financial Consulate’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$672 Hold
13
– – ﹤0.01% 1176
2025
Q4 		$647 Hold
13
– – ﹤0.01% 1096
2025
Q3 		$622 Buy
+13
New +$524 ﹤0.01% 943

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Financial Consulate's SUPN Position: Q1 2026 in Review

Financial Consulate held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 13 shares worth $672. The position accounts for ﹤0.01% of the portfolio, ranked #1176.

Financial Consulate first reported a position in SUPN in Q3 2025 and has held it in 3 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

  • Financial Consulate held 13 shares of Supernus Pharmaceuticals worth $672 as of Q1 2026.
  • Financial Consulate left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Financial Consulate's portfolio in Q1 2026, its #1176 holding.
  • Financial Consulate first reported a position in Supernus Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Financial Consulate's 13F filing for Q1 2026, filed 21 Apr 2026.